Landiolol for Treating Arrhythmias: A State-of-The-Art Review.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
This article provides a state-of-the-art review on landiolol, a medication that was recently submitted for 7 approvals. Focusing on its pharmacology, pharmacokinetics, and pharmacodynamics, the analysis underscores landiolol's unique attributes compared to conventional beta-blockers, particularly esmolol. As a sympatholytic agent, landiolol exhibits a short half-life, high cardioselectivity, and minimal impact on blood pressure, setting it apart in the realm of arrhythmia treatment. The review explores landiolol's potential applications, emphasizing scenarios where other beta-blockers may be limited. A detailed examination of its efficacy in preventing postoperative atrial fibrillation reveals promising results from clinical trials, suggesting its utility in diverse surgical settings. Additionally, the article delves into landiolol's role in rate control for atrial fibrillation/flutter, treatment of ventricular tachycardia/fibrillation, and its use in managing sepsis-related tachyarrhythmias. The evolving landscape of landiolol's applications extends beyond cardiac care, including potential anti-inflammatory, antioxidative, analgesic, and anticancer effects. While the outcomes from various studies are promising, challenges persist, requiring further research to optimize dosing strategies, identify optimal patient populations, and elucidate mechanisms underlying its diverse effects. The potential expansion of landiolol's applications highlights the importance of ongoing clinical investigation, offering a promising avenue for enhancing arrhythmia management and addressing broader medical needs.
Identifiants
pubmed: 38478386
doi: 10.1097/CRD.0000000000000687
pii: 00045415-990000000-00232
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors declare no conflicts of interest.
Références
Goldberger JJ, Cain ME, Hohnloser SH, et al.; American Heart Association. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. Circulation. 2008;118:1497–1518.
Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16:217–221.
Peretto G, Durante A, Limite LR, et al. Postoperative arrhythmias after cardiac surgery: incidence, risk factors, and therapeutic management. Cardiol Res Pract. 2014;2014:615987.
AlTurki A, Marafi M, Proietti R, et al. Major adverse cardiovascular events associated with postoperative atrial fibrillation after noncardiac surgery. Circ Arrhythm Electrophysiol. 2020;13:e007437.
Wiest D. Esmolol. Clin Pharmacokinet. 1995;28:190–202.
Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013;73:959–977.
Sasao J, Tarver SD, Kindscher JD, et al. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth. 2001;48:985–989.
Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40:1462–1469.
Nasrollahi-Shirazi S, Sucic S, Yang Q, et al. Comparison of the β-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions. J Pharmacol Exp Ther. 2016;359:73–81.
Ikeshita K, Nishikawa K, Toriyama S, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22:361–366.
Domanovits H, Wolzt M, Stix G. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl. 2018;20:A1–A3.
Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012;72:109–132.
Krumpl G, Ulč I, Trebs M, et al. Pharmacokinetics and pharmacodynamics of low-, intermediate-, and high-dose landiolol and esmolol during long-term infusion in healthy whites. J Cardiovasc Pharmacol. 2018;71:137–146.
Krumpl G, Ulc I, Trebs M, et al. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy caucasian group. Eur J Clin Pharmacol. 2017;73:417–428.
Taenaka N, Kikawa S. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2013;13:353–364.
Taenaka N, Kikawa S. Dose-dependent effect of landiolol, a new ultra-short-acting β(1)-blocker, on supraventricular tachyarrhythmias in postoperative patients. Clin Drug Investig. 2013;33:505–514.
Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Adv Ther. 2014;31:440–450.
Nagai R, Kinugawa K, Inoue H, et al.; J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77:908–916.
Yoshida Y, Terajima K, Sato C, et al. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008;22:64–69.
Ling LH, Kistler PM, Kalman JM, et al. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol. 2016;13:131–147.
Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–2925.
Chioncel O, Mebazaa A, Harjola VP, et al.; ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19:1242–1254.
Van Gelder IC, Rienstra M, Crijns HJ, et al. Rate control in atrial fibrillation. Lancet. 2016;388:818–828.
Shiga T. Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure. Eur Heart J Suppl. 2022;24(Suppl D):D11–D21.
Aoki Y, Kawasaki Y, Ide K, et al. Landiolol hydrochloride for prevention of atrial fibrillation during esophagectomy: a randomized controlled trial. JA Clin Rep. 2020;6:34.
Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76:439–445.
Horikoshi Y, Goyagi T, Kudo R, et al. The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: a randomized controlled clinical trial. J Clin Anesth. 2017;38:111–116.
Ojima T, Nakamori M, Nakamura M, et al. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg. 2017;104:1003–1009.
Ferraris A, Jacquet-Lagrèze M, Cazenave L, et al. Effects of landiolol on macrocirculatory parameters and left and right ventricular performances following cardiac surgery: a randomized controlled trial. J Cardiothorac Vasc Anesth. 2022;36:2864–2869.
Sasaki K, Kumagai K, Maeda K, et al. Preventive effect of low-dose landiolol on postoperative atrial fibrillation study (PELTA study). Gen Thorac Cardiovasc Surg. 2020;68:1240–1251.
Hao J, Zhou J, Xu W, et al. Beta-blocker landiolol hydrochloride in preventing atrial fibrillation following cardiothoracic surgery: a systematic review and meta-analysis. Ann Thorac Cardiovasc Surg. 2022;28:18–31.
Caspersen E, Guinot PG, Rozec B, et al.; ARCOTHOVA Group. Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial. Trials. 2023;24:353.
Stix G, Wolzt M, Domanovits H, et al. Open-label two-dose pilot study of landiolol for the treatment of atrial fibrillation/atrial flutter in caucasian patients. Circ J. 2019;84:33–42.
Ikeda T, Shiga T, Shimizu W, et al.; J-Land II Study Investigators. Efficacy and safety of the ultra-short-acting β1-selective blocker landiolol in patients with recurrent hemodynamically unstable ventricular tachyarrhymias - outcomes of J-Land II study. Circ J. 2019;83:1456–1462.
Lescroart M, Pequignot B, Kimmoun A, et al. Beta-blockers in septic shock: what is new? J Intensive Med. 2022;2:150–155.
Kakihana Y, Nishida O, Taniguchi T, et al.; J-Land 3S Study Group. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;8:863–872.
Schnaubelt S, Eibensteiner F, Oppenauer J, et al. Hemodynamic and rhythmologic effects of push-dose landiolol in critical care—a retrospective cross-sectional study. Pharmaceuticals (Basel). 2023;16:134.
Unger M, Morelli A, Singer M, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials. 2018;19:637.
Whitehouse T, Hossain A, Perkins GD, et al.; STRESS-L Collaborators. Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. JAMA. 2023;330:1641–1652.
Schroeder L, Monno P, Unger M, et al. Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension. ESC Heart Fail. 2023;10:385–396.
Matsumoto S, Tokumaru O, Ogata K, et al. Dose-dependent scavenging activity of the ultra-short-acting β1-blocker landiolol against specific free radicals. J Clin Biochem Nutr. 2022;71:185–190.
Fu L, Yu B, Li Z, et al. The therapeutic potential of ultra-short-acting β-receptor antagonists in perioperative analgesic: evidence from preclinical and clinical studies. Front Pharmacol. 2022;13:910710.
Yamamoto H, Hamasaki T, Onda K, et al. Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients. Trials. 2019;20:715.